21 results on '"Kitawaki, Toshio"'
Search Results
2. Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan.
- Author
-
Goto, Hideki, Kitawaki, Toshio, Fujii, Nobuharu, Kato, Koji, Onishi, Yasushi, Fukuhara, Noriko, Yamauchi, Takuji, Toratani, Kazunori, Kobayashi, Hiroki, Yoshida, Shota, Shimo, Masatoshi, Onodera, Koichi, Senjo, Hajime, Onozawa, Masahiro, Hirata, Kenji, Yokota, Isao, and Teshima, Takanori
- Subjects
- *
DIFFUSE large B-cell lymphomas , *CYTOKINE release syndrome , *LYMPHOMAS , *CHIMERIC antigen receptors , *FOLLICULAR lymphoma - Abstract
Background: Tisagenlecleucel, an autologous CD19-directed T-cell immunotherapy, can induce a durable response in adult patients with relapsed/refractory (r/r) B-cell lymphoma. Methods: To elucidate the outcome of chimeric antigen receptor (CAR) T-cell therapy in Japanese, we retrospectively analyzed the outcomes of 89 patients who received tisagenlecleucel for r/r diffuse large B-cell lymphoma (n = 71) or transformed follicular lymphoma (n = 18). Results: With a median follow-up of 6.6-months, 65 (73.0%) patients achieved a clinical response. The overall survival (OS) and event-free survival (EFS) rates at 12 months were 67.0% and 46.3%, respectively. Overall, 80 patients (89.9%) had cytokine release syndrome (CRS), and 6 patients (6.7%) had a grade ≥ 3 event. ICANS occurred in 5 patients (5.6%); only 1 patient had grade 4 ICANS. Representative infectious events of any grade were cytomegalovirus viremia, bacteremia and sepsis. The most common other adverse events were ALT elevation, AST elevation, diarrhea, edema, and creatinine elevation. No treatment-related mortality was observed. A Sub-analysis showed that a high metabolic tumor volume (MTV; ≥ 80 ml) and stable disease /progressive disease before tisagenlecleucel infusion were both significantly associated with a poor EFS and OS in a multivariate analysis (P < 0.05). Notably, the combination of these 2 factors efficiently stratified the prognosis of these patients (HR 6.87 [95% CI 2.4–19.65; P < 0.05] into a high-risk group). Conclusion: We report the first real-world data on tisagenlecleucel for r/r B-cell lymphoma in Japan. Tisagenlecleucel is feasible and effective, even in late line treatment. In addition, our results support a new algorithm for predicting the outcomes of tisagenlecleucel. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Anti-inflammatory modulation of human myeloid-derived dendritic cell subsets by lenalidomide.
- Author
-
Yamamoto, Kazuyo, Kitawaki, Toshio, Sugimoto, Naoshi, Fujita, Haruyuki, Kawase, Yumi, Takaori-Kondo, Akifumi, and Kadowaki, Norimitsu
- Subjects
- *
DENDRITIC cells , *THERAPEUTICS , *T cells , *MULTIPLE myeloma , *TRANSCRIPTION factors - Abstract
• Lenalidomide potently suppresses the production of IL-12 and IL-23 by CD1c+ DCs. • Lenalidomide likely targets pathways downstream of NF-κB and IRF5 in CD1c+ DCs. • Lenalidomide suppresses induction of immune activating CD4+ T cells by CD1c+ DCs. Although immunomodulatory drugs (IMiDs) were originally developed as anti-inflammatory drugs, they are effective for multiple myeloma. In order to gain further insights into the immunomodulatory mechanisms of IMiDs for the treatment of inflammatory disorders and myeloma, we investigated the influence of a representative IMiD, lenalidomide, on human primary dendritic cell (DC) subsets: myeloid-derived CD1c+ DCs, CD141+ DCs, and plasmacytoid DCs. Lenalidomide did not affect the viability or expression of costimulatory molecules, but it potently suppressed the production of the key inflammatory cytokines IL-12 and IL-23, and enhanced the production of the anti-inflammatory cytokine IL-10 by CD1c+ DCs. Lenalidomide also suppressed the production of IFN-α by CD141+ DCs but not that by plasmacytoid DCs. Lenalidomide likely targets pathways downstream of the nuclear translocation of the transcription factors nuclear factor κB (NF-κB) and IFN regulatory 5 (IRF5) in CD1c+ DCs. Consistent with the direct immunomodulatory effects on DCs, lenalidomide decreased the capacity of CD1c+ DCs to induce differentiation of naïve CD4+ T cells into effector cells producing immune activating and myeloma-promoting cytokines. This study demonstrated that lenalidomide has anti-inflammatory effects via the modulation of cytokine production by human myeloid-derived DCs. Such effects on DCs may allow for beneficial immunomodulation aiding in the treatment of inflammatory disorders and multiple myeloma. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
4. Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy.
- Author
-
Jo, Tomoyasu, Arai, Yasuyuki, Kitawaki, Toshio, Nishikori, Momoko, Mizumoto, Chisaki, Kanda, Junya, Yamashita, Kouhei, Nagao, Miki, and Takaori-Kondo, Akifumi
- Subjects
- *
LEUKAPHERESIS , *CELLULAR therapy , *HYPERCALCEMIA , *RISK assessment , *BLOOD volume , *ANTIGEN receptors - Abstract
Optimized management of citrate-induced hypocalcemia is required to provide safe leukapheresis. We prospectively analyzed subjects who underwent leukapheresis for cytotherapy, and evaluated serum ionized (iCa) concentrations before, at the end of, and 1 h after leukapheresis. During leukapheresis, calcium gluconate solution was continuously supplemented intravenously with hourly measurement of iCa. 76 patients including 49 lymphapheresis for chimeric antigen receptor T-cell therapy and 27 stem cell collections were enrolled. Median processing blood volume was 10 L (range, 6–15 L). Fluctuating hypercalcemia, in which the iCa concentration rose above its upper limit 1 h after leukapheresis, was observed in 58 subjects (76.3%). Multivariate analysis revealed that higher ratios of processing blood volume to body weight, more rapid calcium supplementation, and lower iCa concentration at the end of leukapheresis significantly increased elevation of serum iCa concentration by 1 h after leukapheresis. Based on multivariate analyses, we developed a formula and a diagram that accurately estimates serum iCa concentration 1 h post-leukapheresis. This suggests optimal targets for iCa concentration and calcium supplementation rates. In cases with high ratios of processing blood volume to body weight, slowing the rate of blood processing, rather than increasing calcium supplementation should safely alleviate hypocalcemia during leukapheresis without inducing hypercalcemia thereafter. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. A phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate.
- Author
-
Kitawaki, Toshio, Kadowaki, Norimitsu, Fukunaga, Keiko, Kasai, Yasunari, Maekawa, Taira, Ohmori, Katsuyuki, Kondo, Takashige, Maekawa, Ryuji, Takahara, Masashi, Nieda, Mie, Kuzushima, Kiyotaka, Ishikawa, Takayuki, and Uchiyama, Takashi
- Subjects
- *
IMMUNOTHERAPY , *ACUTE myeloid leukemia , *DENDRITIC cells , *MESSENGER RNA , *PEPTIDES , *VACCINATION - Abstract
The article presents a phase I/IIa clinical trial of immunotherapy elderly patients who has acute myeloid leukemia (AML) using dendritic cell (DC) with zoledronate and WT1 peptide. It states that the promise of DC-based immunotherapy for AML was shown from a recent report on immunotherapy using WT1 messenger Ribonuceic Acid (mRNA)-electroporated DCs. It mentions that the strengthening of vaccinations may result to an improved clinical outcome.
- Published
- 2011
- Full Text
- View/download PDF
6. Recent Advance in Antigen-Specific Immunotherapy for Acute Myeloid Leukemia.
- Author
-
Kadowaki, Norimitsu and Kitawaki, Toshio
- Subjects
- *
ACUTE myeloid leukemia , *TUMORS , *DENDRITIC cells , *T cells , *IMMUNOTHERAPY - Abstract
Relapse after chemotherapy is inevitable in the majority of patients with acute myeloid leukemia (AML). Thus, it is necessary to develop novel therapies that have different antileukemic mechanisms. Recent advances in immunology and identification of promising leukemia-associated antigens open the possibilities for eradicating minimal residual diseases by antigen-specific immunotherapy after chemotherapy. Several methods have been pursued as immunotherapies for AML: peptide vaccines, granulocyte-macrophage colony-stimulating factor-secreting tumor vaccines, dendritic cell vaccines, and adoptive T cell therapy. Whereas immunogenicity and clinical outcomes are improving in these trials, severe adverse events were observed in highly avid engineered T cell therapies, indicating the importance of the balance between effectiveness and side effects in advanced immunotherapy. Such progress in inducing antitumor immune responses, together with strategies to attenuate immunosuppressive factors, will establish immunotherapy as an important armament to combat AML. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
7. The CD70–CD27 interaction during the stimulation with dendritic cells promotes naive CD4+ T cells to develop into T cells producing a broad array of immunostimulatory cytokines in humans.
- Author
-
Hashimoto-Okada, Mutsumi, Kitawaki, Toshio, Kadowaki, Norimitsu, Iwata, Satoshi, Morimoto, Chikao, Hori, Toshiyuki, and Uchiyama, Takashi
- Subjects
- *
CELL communication , *DENDRITIC cells , *T cells , *IMMUNOLOGICAL adjuvants , *CYTOKINES - Abstract
CD70 expressed on dendritic cells (DCs) has been shown to play a critical role in inducing effective CD8+ T cell responses and a Th1 response in mice. However, it has not been extensively examined whether human primary DCs express CD70 and whether the CD70–CD27 interaction promotes naive CD4+ T cells to acquire the ability to produce effector cytokines during the DC–T cell interaction in humans. Here, we show that human myeloid dendritic cells (mDCs) and plasmacytoid dendritic cells stimulated with CD40 ligand together with pro-inflammatory cytokines or Toll-like receptor ligands express CD70. Thymic stromal lymphopoietin plus prostaglandin E2 also induced CD70 on mDCs. Naive CD4+ T cells stimulated with DCs but not with anti-CD3/CD28 microbeads expressed CD70. Stimulation with CD70 together with anti-CD3/CD28 microbeads imparted the ability to produce Th1 (IFN-γ), Th2 (IL-4, IL-5, IL-13) cytokines, IL-2 and tumor necrosis factor-α to naive CD4+ T cells. The production of IFN-γ was associated with the induction of T-bet. Naive CD4+ T cells stimulated with mDCs acquired an enhanced ability to produce a broad array of immunostimulatory cytokines in a CD70-dependent manner. These data suggest that human CD70 expressed on mDCs and activated T cells transmits a ‘basal level’ signal, rather than a ‘polarizing’ signal, to naive CD4+ T cells, in that CD70 promotes the development of CD4+ T cells that produce a variety of effector cytokines including both Th1 and Th2 types, thus contributing to the enhancement of a broad spectrum of immune responses. [ABSTRACT FROM PUBLISHER]
- Published
- 2009
- Full Text
- View/download PDF
8. Utilizing red blood cell distribution width (RDW) as a reliable biomarker to predict treatment effects after chimeric antigen receptor T cell therapy.
- Author
-
Nakamura, Naokazu, Jo, Tomoyasu, Arai, Yasuyuki, Kitawaki, Toshio, Nishikori, Momoko, Mizumoto, Chisaki, Kanda, Junya, Yamashita, Kouhei, Nagao, Miki, and Takaori-Kondo, Akifumi
- Subjects
- *
CHIMERIC antigen receptors , *ERYTHROCYTES , *CELLULAR therapy , *B cell lymphoma , *BIOMARKERS - Abstract
Chimeric antigen receptor T cell (CAR-T) therapy is an effective treatment for B cell malignancies. A certain fraction of patients, however, experience post-CAR-T relapse, and due to the difficulty of precise relapse prediction, biomarkers that can predict the strength and duration of CAR-T efficacy are needed before CAR-T infusion. Therefore, we performed a single-center cohort study including 91 diffuse large B cell lymphoma (DLBCL) patients treated with CAR-T in order to identify such a new prognostic biomarker. After confirming that each of the already reported prognostic parameters (disease status at leukapheresis, primary refractoriness, number of treatment lines, CD3+ cell counts at leukapheresis) has only limited predictive performance, we established a new composite parameter by integrating these four variables, and found that it predicts progression-free survival (PFS) after CAR-T infusion with statistical significance. Moreover, after comprehensive correlation analyses of this new composite parameter with all individual laboratory variables, we determined that the standard deviation of red blood cell distribution width (RDW-SD) at leukapheresis shows significant correlation with the composite parameter and may be a prognostic biomarker (R2 = 0.76, p = 0.02). Validation analysis indicated that a higher RDW-SD is significantly associated with poorer PFS after CAR-T cell therapy (HR, 3.46, P = 0.03). Thus, this study suggests that a single parameter, RDW-SD at leukapheresis, is a novel, useful biomarker that can be obtained early to predict therapeutic effects of CAR-T cell therapy. Post-CAR-T maintenance or re-induction therapies should be adopted for higher risk patients, who may relapse after CAR-T therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T‐cell therapy.
- Author
-
Nakamura, Naokazu, Arai, Yasuyuki, Kitawaki, Toshio, Jo, Tomoyasu, Mizumoto, Chisaki, Kanda, Junya, Nishikori, Momoko, Yamashita, Kouhei, and Takaori‐Kondo, Akifumi
- Subjects
- *
CYTOKINE release syndrome , *CHIMERIC antigen receptors , *HYPOPHOSPHATEMIA , *T cells , *DIFFUSE large B-cell lymphomas - Abstract
Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T-cell therapy Key sentences CD19-targeted chimeric antigen receptor T cell (CAR-T) therapy is an innovative treatment[1] for patients with diffuse large B-cell lymphoma (DLBCL). Keywords: chimeric antigen receptor T cell (CAR-T); cytokine release syndrome (CRS); hypophosphataemia; predictive marker EN chimeric antigen receptor T cell (CAR-T) cytokine release syndrome (CRS) hypophosphataemia predictive marker e1 e3 3 12/22/22 20230101 NES 230101 Decreased serum iP can be a predictive marker for subsequent severe CRS. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
10. Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan.
- Author
-
Iemura, Tomoki, Kondo, Tadakazu, Ueda, Atsushi, Maeda, Takeshi, Kitawaki, Toshio, Arai, Yasuyuki, Kanda, Junya, Ikeda, Takashi, Imada, Kazunori, Ishikawa, Takayuki, Anzai, Naoyuki, Itoh, Mitsuru, Takeoka, Tomoharu, Akasaka, Takashi, Yago, Kazuhiro, Yonezawa, Akihito, Arima, Nobuyoshi, Kitano, Toshiyuki, Nohgawa, Masaharu, and Watanabe, Mitsumasa
- Subjects
- *
DRUG monitoring , *HEMATOPOIETIC stem cell transplantation , *BUSULFAN , *DRUG interactions - Abstract
Although exposure-directed busulfan (BU) dosing can improve allogeneic hematopoietic stem cell transplantation outcomes, there is still large variability in BU exposure with test dose alone due to changes in BU clearance caused by drug interactions. We conducted a single-arm phase II trial using the combined test dose and therapeutic drug monitoring strategy (PK-guided group) and compared the outcomes with an external historical cohort receiving a fixed-dose (fixed-dose group). The first eight and second eight doses were adjusted based on the area under the blood concentration-time curve (AUC) of the test and first doses, respectively, targeting a total AUC of 82.1 mg·h/L. All patients received either BU and cyclophosphamide conditioning (BU/CY) or fludarabine (FLU)-containing conditioning. The BU clearance at the first dose decreased more in patients receiving FLU than in those receiving BU/CY; however, BU clearance also declined over time in patients who received BU/CY. The simulated total AUC (sAUC) with test dose only was significantly higher in patients who received FLU than in those who received BU/CY, but sAUC with the combined strategy was comparable. The 100-day progression-free survival was 85.5% (95% confidence interval [CI]: 71.9–92.8%), and was not inferior to that in the fixed-dose group. For the FLU-containing regimens, the PK-guided group showed decreased relapse (0.0% vs. 26.9%, p = 0.03), and favorable overall survival (75.1% vs. 57.0%, p = 0.07) at 1 year. The combined strategy effectively controlled the BU exposure close to the target levels, potentially improving efficacy, especially in patients receiving the FLU-containing regimen. Clinical evaluation of efficacy of dose-modified intravenous busulfan in allogeneic hematopoietic stem cell transplantation for hematological malignancy (#UMIN000014077, June 15th, 2014). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Acute myeloid leukemia with a cryptic NUP98/PRRX2 rearrangement developing after low-dose methotrexate therapy for rheumatoid arthritis.
- Author
-
Chonabayashi, Kazuhisa, Yoshida, Yoshinori, Kitawaki, Toshio, Nannya, Yasuhito, Nakamura, Momoko, Oshima, Shinichiro, Hishizawa, Masakatsu, Yamashita, Kouhei, Ogawa, Seishi, and Takaori-Kondo, Akifumi
- Subjects
- *
ACUTE myeloid leukemia , *RHEUMATOID arthritis , *POLYCYTHEMIA vera , *CHROMOSOMAL translocation ,BONE marrow examination - Abstract
Chromosomal translocations juxtaposing the class II homeobox gene I PRRX2 i with I NUP98 i loci have been reported in therapy-related acute myeloid leukemia (AML), but their clinical significance is unclear [[2]]. There have been some reports of AML development in rheumatoid arthritis patients treated with MTX, although it remains unclear whether low-dose MTX therapy may serve a role in pathogenesis of AML [[4]]. [Extracted from the article]
- Published
- 2019
- Full Text
- View/download PDF
12. T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy.
- Author
-
Wada, Fumiya, Jo, Tomoyasu, Arai, Yasuyuki, Kitawaki, Toshio, Mizumoto, Chisaki, Kanda, Junya, Nishikori, Momoko, Yamashita, Kouhei, Nagao, Miki, and Takaori-Kondo, Akifumi
- Subjects
- *
LEUKAPHERESIS , *CELLULAR therapy , *DIFFUSE large B-cell lymphomas , *LYMPHOCYTE count , *RECEIVER operating characteristic curves , *BLOOD cell count , *T cells , *CHIMERIC antigen receptors - Abstract
Prediction of responses to chimeric antigen receptor (CAR)-T cell therapies is essential to maximize their therapeutic efficacy for diffuse large B-cell lymphoma (DLBCL). While several tumor-intrinsic risk factors of resistance and/or early relapse have been identified, clinically useful markers that determine potential activity of CAR-T cells have not been fully investigated. T-cell property at the time of leukapheresis may serve as such a marker. Therefore, we evaluated the clinical impact of CD3+ cell count in peripheral blood at leukapheresis on clinical outcomes of CAR-T cell therapy. In total, 44 patients with relapsed or refractory (r/r) DLBCL who received tisagenlecleucel at Kyoto University Hospital were included. According to CD3+ cell counts, patients were categorized into CD3LOW and CD3HIGH groups with a threshold of 553/μL, based on receiver operating characteristic curve analysis. 1-year progression-free survival was significantly higher in the CD3HIGH group than the CD3LOW group (68.3% vs. 17.3%; adjusted hazard ratio [aHR], 0.37; p = 0.042). Overall survival was also superior in the CD3HIGH group (aHR, 0.24; p = 0.043). Moreover, higher CD3+ cell counts at leukapheresis were associated with significantly higher lymphocyte counts in peripheral blood at day 7 after CAR-T cell infusion (median 860 vs. 420/μL, P = 0.021), suggesting more extensive expansion of infused CAR-T cells in vivo. In conclusion, we demonstrated that the CD3+ cell count at leukapheresis predicts both expansion of CAR-T cells after infusion and outcomes of CAR-T cell therapy, and are useful for building comprehensive therapeutic strategies at the time of leukapheresis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Cross-priming of CD8+ T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia
- Author
-
Kitawaki, Toshio, Kadowaki, Norimitsu, Fukunaga, Keiko, Kasai, Yasunari, Maekawa, Taira, Ohmori, Katsuyuki, Itoh, Tatsuya, Shimizu, Akira, Kuzushima, Kiyotaka, Kondo, Tadakazu, Ishikawa, Takayuki, and Uchiyama, Takashi
- Subjects
- *
T cells , *DENDRITIC cells , *APOPTOSIS , *IMMUNOTHERAPY , *ACUTE myeloid leukemia , *HEALTH outcome assessment , *CLINICAL trials , *DRUG therapy , *PATIENTS - Abstract
Objective: The prognosis for elderly patients with acute myeloid leukemia (AML) remains dismal. To explore the potential of immunotherapy for improving clinical outcomes for these patients, we performed a phase I clinical trial of dendritic cell (DC)−based immunotherapy for elderly patients with AML. Materials and Methods: Autologus monocytes were obtained after reducing tumor burden by chemotherapy. Immature DCs induced with granulocyte-macrophage colony-stimulating factor and interleukin-4 were pulsed with autologous apoptotic leukemic cells as antigens. DCs were administered intradermally to four patients five times at 2-week intervals. To facilitate DC migration to lymph nodes, injection sites were pretreated with killed Streptococcus pyogenes OK-432 one day before. DCs were coinjected with OK-432 to induce maturation and interleukin-12 production in vivo. Results: Antileukemic responses were observed by an interferon-γ enzyme-linked immunospot assay or a tetramer assay in two of four patients. In a human leukocyte antigen−A∗2402-positive patient, induction of CD8+ T-cell responses to WT1- and human telomerase reverse transcriptase – derived peptides were observed, indicating cross-priming in vivo. The two patients with antileukemic immunity showed longer periods of disease stabilization than the other two patients. Conclusions: This study demonstrates the immunogenicity of autologous DCs that cross-present leukemia-associated antigens from autologous apoptotic leukemic cells in vivo in elderly patients with AML. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
14. Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era.
- Author
-
Ishii, Akira, Jo, Tomoyasu, Arai, Yasuyuki, Oshima, Shinichiro, Kanda, Junya, Kitawaki, Toshio, Matsui, Keiko, Niwa, Norimi, Nakagawa, Yoko, Takaori-Kondo, Akifumi, and Nagao, Miki
- Subjects
- *
LEUKAPHERESIS , *STEM cells , *BLOOD cells , *STEM cell transplantation , *PREDICTION models , *MULTIPLE myeloma - Abstract
Predicting autologous peripheral blood stem cell (PBSC) collection yield before leukapheresis is important for optimizing PBSC mobilization and autologous stem cell transplantation (ASCT) for treating hematological malignancies. Although guidelines for plerixafor usage based on peripheral blood CD34+ (PB-CD34+) cell count are available, their predictive performance in the real world remains unclear. This study retrospectively analyzed 55 mobilization procedures for patients with non-Hodgkin lymphoma or multiple myeloma and developed a novel quantitative prediction model for CD34+ cell collection yield that incorporated four clinical parameters available the day before leukapheresis; namely, PB-CD34+ cell count the day before apheresis (day −1 PB-CD34+), number of prior chemotherapy regimens, disease status at apheresis and mobilization protocol. The effects of PB-CD34+ cell counts on CD34+ cell collection yield varied widely per patient characteristics, and plerixafor usage was recommended in patients with poorly controlled disease or those with a history of heavy pre-treatments even with abundant day −1 PB-CD34+ cell count. This model suggested a more proactive use of plerixafor than that recommended by the guidelines for patients with poor pre-collection condition or those with a higher target number of CD34+ cells. Further, the authors analyzed the clinical outcomes of ASCT and found that plerixafor use for stem cell mobilization did not affect short- or long-term outcomes after ASCT. Although external validations are necessary, the results can be beneficial for establishing more effective and safer mobilization strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Optimal stimulation for CD70 induction on human monocyte-derived dendritic cells and the importance of CD70 in naive CD4+ T-cell differentiation.
- Author
-
Arimoto-Miyamoto, Kazue, Kadowaki, Norimitsu, Kitawaki, Toshio, Iwata, Satoshi, Morimoto, Chikao, and Uchiyama, Takashi
- Subjects
- *
LYMPHOCYTES , *DENDRITIC cells , *CELL differentiation , *CELL communication , *INFLAMMATORY mediators - Abstract
Studies in mice have shown that CD70 on dendritic cells (DCs) is sufficient to convert T-cell tolerance into immunity and hence induce anti-tumour immune responses. Therefore, it is important to investigate (i) optimal stimuli to induce CD70 on human monocyte-derived DCs (MoDCs), which are widely used for tumour immunotherapy, and (ii) the role of CD70 in functional differentiation of naive CD4+ and CD8+ T cells stimulated with MoDCs. We show that interferon-α (IFN-α) is a key cytokine to differentiate monocytes into DCs with the capacity to express CD70 upon maturation. CD70 expression on IFN-α-induced MoDCs was elicited by different categories of maturation-inducing factors (Toll-like receptor ligands, CD40 ligand and pro-inflammatory mediators), among which prostaglandin E2 was most effective. Naive T cells stimulated with MoDCs also expressed CD70. Stimulation with MoDCs promoted naive CD4+ T cells to acquire the ability to produce T helper type 1 and 2 cytokines in a CD70-dependent manner. In contrast, the CD70–CD27 interaction diminished the production of an immunoregulatory cytokine IL-10. The CD27 signal did not play a dominant role in the induction of effector molecules in naive CD8+ T cells during the stimulation with MoDCs. This study adds a novel function to the versatile cytokines, type I IFNs, that is, the induction of CD70 on MoDCs. CD70 promotes naive CD4+ T cells to acquire immunostimulatory activity through the DC–T-cell and T-cell–T-cell interactions during the stimulation with MoDCs. Hence, the CD70–CD27 interaction may play an important role in inducing effective immune responses in DC-based immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
16. Depletion and impaired interferon- α-producing capacity of blood plasmacytoid dendritic cells in human T-cell leukaemia virus type I-infected individuals.
- Author
-
Hishizawa, Masakatsu, Imada, Kazunori, Kitawaki, Toshio, Ueda, Maki, Kadowaki, Norimitsu, and Uchiyama, Takashi
- Subjects
- *
LEUKEMIA , *DENDRITIC cells , *IMMUNITY , *ANTIVIRAL agents , *INTERFERONS , *T cells , *PATIENTS - Abstract
Dendritic cells (DCs) play an important role in innate and adaptive immunity. There are two major populations of blood DCs, myeloid DCs (myDCs) and plasmacytoid DCs (pcDCs). pcDCs are particularly important in antiviral as well as in general host defence, as they are the principal producers of type I interferons (IFNs). In this study, we analysed myDCs and pcDCs in healthy controls, human T-cell leukaemia virus type I (HTLV-I)-infected asymptomatic carriers (ACs), and patients with adult T-cell leukaemia (ATL). ATL patients had significantly decreased number of pcDCs and myDCs compared with controls. IFN- α production by peripheral blood mononuclear cells (PBMCs) was markedly reduced in ATL patients. Purified pcDCs from ACs were found to have impaired IFN- α-producing capacity, suggesting a functional defect in pcDCs in HTLV-I-infected individuals. Interestingly, pcDCs were shown to be susceptible to HTLV-I infection. Thus, impaired IFN- α production by pcDCs may contribute to the immunodeficiency observed in ATL. Furthermore, IFN- α-producing capacity was inversely correlated with HTLV-I proviral load in PBMCs from ACs, suggesting a role for pcDCs in maintaining the carrier state. Taken together, we hypothesize that the depletion and impaired IFN- α-producing capacity of blood DCs may contribute to the immunodeficiency in ATL and/or the development of ATL. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
17. EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas.
- Author
-
Otsuka, Yasuyuki, Nishikori, Momoko, Arima, Hiroshi, Izumi, Kiyotaka, Kitawaki, Toshio, Hishizawa, Masakatsu, and Takaori-Kondo, Akifumi
- Subjects
- *
KILLER cells , *T cells , *RITUXIMAB , *CELL lines , *CELL tumors - Abstract
• Loss of CD58 is a common mechanism for immune evasion in lymphoid malignancies. • EZH2 inhibitors restore epigenetically suppressed CD58 expression of lymphoma cells. • EZH2 inhibitors enhance IFN-γ production of T and NK cells against lymphoma cells. Loss of CD58 is a common mechanism for tumor immune evasion in lymphoid malignancies. CD58 loss is known to occur due to both genetic and non-genetic causes; therefore, we hypothesized that restoring CD58 expression in lymphoma cells may be an effective treatment approach. To explore the potential for restoring CD58 expression, we first screened 11 B-cell lymphoma lines and found that 3 had decreased CD58 expression. Among these, CD58 was genetically damaged in two lines but not in the third line. Using the cell line with downregulated CD58 without a genetic abnormality, we performed epigenetic library screening and found that two EZH2 inhibitors, EPZ6438 and GSK126, specifically enhanced CD58 expression. By examining the effect of three EZH2 inhibitors with different selectivity profiles in different B-cell lines, EZH2 inhibition was shown to have a common activity in upregulating CD58 expression. Restoring the expression of CD58 in lymphoma cells using an EZH2 inhibitor was shown to enhance interferon-γ production of T and NK cells against lymphoma cells. H3K27 was shown to be highly trimethylated in the CD58 promoter region, and EZH2 inhibition induced its demethylation and activated transcription of the CD58 gene. These results indicated that EZH2 is involved in the epigenetic silencing of CD58 in lymphoma cells as a mechanism for tumor immune escape, and EZH2 inhibitors are able to restore epigenetically suppressed CD58 expression. Our findings provide a molecular basis for the combination of an EZH2 inhibitor and immunotherapy for lymphoma treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
- Author
-
Yamauchi, Ichiro, Yasoda, Akihiro, Matsumoto, Shigemi, Sakamori, Yuichi, Kim, Young Hak, Nomura, Motoo, Otsuka, Atsushi, Yamasaki, Toshinari, Saito, Ryoichi, Kitamura, Morimasa, Kitawaki, Toshio, Hishizawa, Masakatsu, Kawaguchi-Sakita, Nobuko, Fujii, Toshihito, Taura, Daisuke, Sone, Masakatsu, and Inagaki, Nobuya
- Subjects
- *
THYROID gland , *ADVERSE health care events , *THERAPEUTICS , *MELANOMA , *PROGNOSIS , *CANCER prognosis - Abstract
Background: Blocking the PD-1 pathway induces immune-related adverse events (irAEs) which often involve the thyroid gland (thyroid irAEs). Clinical features of a thyroid irAE including its predictability and relationship to prognosis remain to be elucidated. Methods: Two hundred consecutive patients treated with nivolumab at Kyoto University Hospital between September 1, 2014 and August 31, 2017 were included in a retrospective cohort study. We systematically determined and classified subclinical and overt thyroid irAEs based on data collected of serum free T4 and TSH levels. Baseline characteristics and detailed clinical data were analyzed, and analyses of overall survival (OS) excluded patients censored within 1 month from the first administration of nivolumab. Results: Sixty-seven patients (33.5%) developed thyroid irAEs and these were divided into a subclinical thyroid irAE group (n = 40, 20.0%) and an overt thyroid irAE group (n = 27, 13.5%). Patients with thyroid uptake of FDG-PET before treatment showed high incidences of overt thyroid irAE (adjusted odds ratio 14.48; 95% confidence interval [CI] 3.12–67.19), while the same relationship was not seen with subclinical thyroid irAE. Regarding the total cohort, the thyroid irAE (+) group had a significantly longer median OS than the thyroid irAE (−) group (16.1 versus 13.6 months, hazard ratio [HR] 0.61; 95% CI 0.39–0.93). In 112 non-excluded patients with lung cancer, the thyroid irAE (+) group similarly had a longer median OS than the thyroid irAE (−) group (not reached versus 14.2 months, HR 0.51; 95% CI 0.27–0.92). However, this observation was not seen in 41 non-excluded patients with malignant melanoma (12.0 versus 18.3 months, HR 1.54; 95% CI 0.67–3.43). Conclusions: By thyroid uptake of FDG-PET, overt thyroid irAEs could be predicted before nivolumab therapy. Thyroid irAEs related to good prognosis in lung cancer but might be inconclusive in malignant melanoma. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. Expression of Tim-1 in primary CNS lymphoma.
- Author
-
Kishimoto, Wataru, Nishikori, Momoko, Arima, Hiroshi, Miyoshi, Hiroaki, Sasaki, Yuya, Kitawaki, Toshio, Shirakawa, Kotaro, Kato, Takeharu, Imaizumi, Yoshitaka, Ishikawa, Takayuki, Ohno, Hitoshi, Haga, Hironori, Ohshima, Koichi, and Takaori ‐ Kondo, Akifumi
- Subjects
- *
TREATMENT of central nervous system cancer , *INTERLEUKINS , *CEREBROSPINAL fluid , *B cells , *IMMUNOHISTOCHEMISTRY , *HEPATITIS A virus cellular receptors - Abstract
Primary central nervous system lymphoma ( PCNSL) is a distinct subtype of extranodal lymphoma with aggressive clinical course and poor outcome. As increased IL-10/ IL-6 ratio is recognized in the cerebrospinal fluid ( CSF) of PCNSL patients, we hypothesized that PCNSL might originate from a population of B cells with high IL-10-producing capacity, an equivalent of 'regulatory B cells' in mice. We intended in this study to clarify whether Tim-1, a molecule known as a marker for regulatory B cells in mice, is expressed in PCNSL. By immunohistochemical analysis, Tim-1 was shown to be positive in as high as 54.2% of PCNSL (26 of 58 samples), while it was positive in 19.1% of systemic diffuse large B-cell lymphoma ( DLBCL) samples (17 of 89 samples; P < 0.001). Tim-1 expression positively correlated with IL-10 expression in PCNSL (Cramer's V = 0.55, P < 0.001), and forced expression of Tim-1 in a PCNSL cell line resulted in increased IL-10 secretion, suggesting that Tim-1 is functionally linked with IL-10 production in PCNSL. Moreover, soluble Tim-1 was detectable in the CSF of PCNSL patients, and was suggested to parallel disease activity. In summary, PCNSL is characterized by frequent Tim-1 expression, and its soluble form in CSF may become a useful biomarker for PCNSL. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
20. Natural Alpha Interferon-Producing Cells Respond to Human Immunodeficiency Virus Type 1 with Alpha Interferon Production and Maturation into Dendritic Cells.
- Author
-
Yonezawa, Akihito, Morita, Rimpei, Takaori-Kondo, Akifumi, Kadowaki, Norimitsu, Kitawaki, Toshio, Hori, Toshiyuki, and Uchiyama, Takashi
- Subjects
- *
CELLS , *INTERFERONS , *DENDRITIC cells , *IMMUNITY , *HIV - Abstract
Natural alpha interferon (IFN-α)-producing cells (IPCs) are now recognized as identical to plasmacytoid dendritic cell (DC) precursors in human blood and are thought to play an important role in antiviral immunity. In the present study, we examined the susceptibility as well as the cellular responses of IPCs to human immunodeficiency virus type 1 (HIV-1) infection. HLA-DR[sup +] CD11c[sup -] lineage-negative cells (IPCs) were purified from peripheral blood mononuclear cells by magnetic-bead separation and cell sorting. We substantiated that IPCs expressing the major HIV-1 coreceptors, CXCR4 and CCR5, are susceptible to infection of both T-cell-line-tropic NL4-3 and macrophage-tropic JR-CSF HIV-1 by quantification of HIV-1 p24 in the culture supernatants and by provirus integration assay using human conserved Alu-HIV-1 long terminal repeat PCR. To evaluate the cellular response of IPCs to HIV-1, we examined IFN-α production and their differentiation into DCs. After incubation with either NL4-3 or JR-CSF, IPCs produced a large amount of IFN-α and at the same time underwent morphological differentiation into DCs with upregulation of CD80 and CD86. Heat inactivation of the supernatants containing HIV-1 did not affect the IFN-α production and maturation, whereas removal of virions by ultracentrifugation completely nullified both biological effects, indicating that these cellular responses do not require actual HIV-1 infection but are elicited by interaction with HIV-1 virions or certain viral components. In conclusion, these data strongly suggest that IPC can directly recognize and respond to HIV-1 with IFN-α production, which is crucial for preventing progress of HIV-1 infection and occurrence of opportunistic infection. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
21. Impact of HLA class I allele-level mismatch on viral infection within 100 days after cord blood transplantation.
- Author
-
Iemura, Tomoki, Arai, Yasuyuki, Kanda, Junya, Kitawaki, Toshio, Hishizawa, Masakatsu, Kondo, Tadakazu, Yamashita, Kouhei, and Takaori-Kondo, Akifumi
- Subjects
- *
CORD blood transplantation , *HLA histocompatibility antigens , *GENE frequency , *VIRUS diseases , *GRAFT versus host disease - Abstract
Viral infection is more frequently reported in cord blood transplantation (CBT) than in transplantation of other stem cell sources, but its precise mechanism related to antiviral host defenses has not been elucidated yet. To evaluate the effect of human leukocyte antigen (HLA) class I allele-level incompatibility on viral infection in CBT, we conducted a single-center retrospective study. Total 94 patients were included, and viral infections were detected in 32 patients (34%) within 100 days after CBT. HLA-C mismatches in graft-versus-host direction showed a significantly higher incidence of viral infection (hazard ratio (HR), 3.67; p = 0.01), while mismatches in HLA-A, -B, or -DRB1 were not significant. Overall HLA class I mismatch was also a significant risk factor and the predictor of post-CBT viral infection (≥ 3 mismatches, HR 2.38, p = 0.02), probably due to the insufficient cytotoxic T cell recognition and dendritic cell priming. Patients with viral infection had significantly worse overall survival (52.7% vs. 72.1%; p = 0.02), and higher non-relapse mortality (29.3% vs. 9.8%; p = 0.01) at 5 years. Our findings suggest that appropriate graft selection as well as prophylaxis and early intervention for viral infection in such high-risk patients with ≥ 3 HLA class I allele-level mismatches, including HLA-C, may improve CBT outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.